Scientists Discover a Hidden Alzheimer's Trigger — And a Drug That Could Stop It

A Breakthrough Decades in the Making

Researchers at ETH Zurich have identified a previously overlooked biological trigger behind Alzheimer's disease and developed an experimental compound capable of blocking it. In animal studies, the treatment slowed the death of nerve cells, reduced hallmark signs of Alzheimer's, and even appeared to support healthier aging overall.

The discovery is the result of nearly 20 years of dedicated research led by Ursula Quitterer, Professor of Molecular Pharmacology at ETH Zurich, and represents a meaningful step forward in understanding one of the world's most complex neurological diseases.

The Protein at the Center of It All

The story begins almost two decades ago, when Quitterer received brain tissue samples from a colleague at Ain Shams University Hospital in Cairo. Collected during tumor surgeries, the samples came from both patients living with dementia and healthy individuals, providing a rare opportunity to compare brain activity at the cellular level.

Those samples set Quitterer's team on the trail of a regulatory protein called GRK2. Under normal circumstances, GRK2 plays a vital role across multiple organs — including the heart and brain — helping cells process signals and manage stress. However, the ETH Zurich team found that something goes seriously wrong with this protein in the context of Alzheimer's disease.

GRK2 exists in two distinct forms inside cells: an active version that functions normally and an inactive version produced through natural cellular processes. The researchers discovered that the inactive form accumulates in abnormally high quantities within the brain tissue of dementia patients. The same pattern was replicated in mice bred to develop Alzheimer's-like symptoms, strengthening the link between GRK2 buildup and the disease.

Their findings were published in the peer-reviewed journal Cell Reports Medicine.

How GRK2 Fuels a Destructive Cycle

The danger doesn't stop at simple accumulation. Further investigation revealed that inactive GRK2 molecules clump together inside nerve cells, forming clusters that latch onto mitochondria — the energy-producing structures essential to cell survival.

"The GRK2 aggregates block the pores of the mitochondria, reducing the amount of energy they can supply and leading to a situation of stress inside the cells," Quitterer explains.

This energy disruption has a cascading effect. The team also found that inactive GRK2 ramps up production of amyloid beta, the protein fragment long associated with Alzheimer's disease progression. Elevated amyloid beta, in turn, creates more cellular stress — which drives even greater production of inactive GRK2. The result is a self-reinforcing cycle that steadily accelerates the disease.

Introducing Compound 10

To break this destructive loop, Quitterer's team designed and tested a series of experimental compounds in both cell cultures and mouse models. One candidate stood out decisively: Compound 10.

The compound works by preventing inactive GRK2 molecules from clustering together in the first place. With aggregation blocked, mitochondria regain their ability to produce energy effectively. Downstream effects included a reduction in amyloid beta deposits, improved nerve cell survival, and a measurable slowdown in cell death.

Beyond the brain, Compound 10 also showed unexpected benefits. Treated mice demonstrated improved heart function and experienced fewer signs of age-related deterioration — including, notably, developing fewer gray hairs as they aged.

Why It Took Nearly Two Decades

The slow pace of the research is largely a reflection of the unique challenges Alzheimer's science presents. Because the disease is age-related, experiments must be conducted using older mice — animals typically between one and a half to two years old. Each experiment demanded the same extended timeline before conclusions could be drawn and the next phase of work could begin.

"It took so long simply because everything takes so long in Alzheimer's research," Quitterer acknowledges. "It's all a great deal slower than in cancer research, for example."

ETH Zurich has since filed a patent application for Compound 10, and the team has completed the foundational research phase.

A New Direction for Alzheimer's Treatment

The researchers are currently seeking a pharmaceutical partner to advance Compound 10 toward clinical drug development. While existing Alzheimer's medications can, at best, delay the disease's progression by a matter of months, this new compound operates through an entirely different mechanism — one that no current approved drug addresses.

"That's why it's so important that we've now identified a new target protein in the form of GRK2, as well as an active ingredient that operates via GRK2 and therefore via a different mechanism than existing Alzheimer's drugs," Quitterer says.

Significantly more research — including human clinical trials — will be required before Compound 10 can be considered a viable treatment option. Nevertheless, scientists believe that combining it with existing therapies could one day yield substantially better outcomes for patients, potentially improving both the quality and duration of life for millions affected by Alzheimer's disease worldwide.